Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: A prospective randomized double-blind clinical trial

Piero Ruggenenti, Dario Cattaneo, Stefano Rota, Ilian Iliev, Aneliya Parvanova, Olimpia Diadei, Bogdan Ene-Iordache, Silvia Ferrari, Antonio C. Bossi, Roberto Trevisan, Antonio Belviso, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE - To assess the effects of inhibited gastrointestinal cholesterol absorption in statin-treated dyslipidemic patients. RESEARCH DESIGN AND METHODS - In a multicenter prospective randomized double-blind placebo-controlled trial, we primarily compared by ANCOVA the effect of 2-month ezetimibe (10 mg/day) or placebo therapy on LDL cholesterol serum levels in 108 type 2 diabetic patients with albuminuria 135 mg/dl despite simvastatin treatment (40 mg/day). RESULTS - Unlike placebo, ezetimibe decreased LDL cholesterol from 99 ± 31 to 66 ± 22 mg/dl, total cholesterol from 162 ± 36 to 124 ± 30 mg/dl, and apolipoprotein B from 83 ± 22 to 64 ± 18 mg/dl (P <0.0001 for all changes versus placebo). A total of 72 and 17% of patients on ezetimibe or placebo achieved LDL levels

Original languageEnglish
Pages (from-to)1954-1956
Number of pages3
JournalDiabetes Care
Volume33
Issue number9
DOIs
Publication statusPublished - Sep 2010

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Fingerprint Dive into the research topics of 'Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: A prospective randomized double-blind clinical trial'. Together they form a unique fingerprint.

Cite this